FDA jurisdiction
What is misbranding, and is it different from selling something dangerous?
Plain English first, then the primary source. Education, not legal advice.
Interpretation
In short: misbranding is a labeling and communication problem, and it can exist even when a product is exactly what it claims to be chemically.
Plain English
Misbranding is a labeling and claims concept, separate from whether a product is actually harmful. Under 21 U.S.C. 352, a drug or device is misbranded if its labeling is false or misleading in any particular, if required information is missing, or if directions for use are inadequate, among other grounds.
A product can be perfectly pure and still be misbranded because of what its label or marketing says. Conversely, accurate labeling does not excuse other violations, such as being an unapproved new drug.
Misbranding and adulteration are both enforcement tools FDA uses, and they often appear together in warning letters and legal actions.
Why it matters
- Sellers should understand that 'the chemical itself is fine' is not a defense to a misbranding claim about label language or marketing statements.
Where the answer becomes fact-specific
The Foundation does not manufacture legal conclusions. These points change the analysis and may require qualified regulatory counsel.
- Whether specific label statements are 'false or misleading' is evaluated in the full context of labeling and advertising, not single sentences in isolation.
View the source
- 21 U.S.C. 352, misbranded drugs and devices, 21 U.S.C. § 352